• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    7/5/24 4:14:38 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email
    SC 13D/A 1 opk20240613_sc13da.htm SCHEDULE 13D/A opk20240613_sc13da.htm

     



     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3*)

     

    GeneDx Holdings, Corp.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    81663L200

    (CUSIP Number)

     

    Steven D. Rubin

    Executive Vice President - Administration

    OPKO Health, Inc.

    4400 Biscayne Boulevard

    Miami, Florida 33137

    Telephone: (305) 575-4100

     

    (Name, address and telephone number of person authorized to receive notices and communications)

     

     

    July 3, 2024

    (Date of event which requires filing of this statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box  ☐.

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     



     

     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 2 of 4

     

     

    1

     

    NAME OF REPORTING PERSONS

     

    OPKO Health, Inc.

    2

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)  ☐        (b)  ☐

    3

     

    SEC USE ONLY

     

    4

     

    SOURCE OF FUNDS

     

    OO

    5

     

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) ☒

     

    6

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    7

     

    SOLE VOTING POWER

     

    NUMBER OF     3,469,521

    Shares

    SHARES

    BENEFICIALLY

    8

     

    SHARED VOTING POWER

     

    OWNED BY

        -  

    EACH REPORTING

    PERSON

    9

     

    SOLE DISPOSITIVE POWER

     

    WITH     3,469,521  
     

    10

     

    SHARED DISPOSITIVE POWER

     

          -  

    11

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

        3,469,521  

    12

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ☐

     

    13

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

       

    13.27%(1)

    14

     

    TYPE OF REPORTING PERSON

     

    CO

     

    (1)

    Based on 26,15,866 shares of GeneDx Common Stock (as defined herein) of the Issuer (as defined herein) outstanding on April 24, 2024, as set forth in the Issuer’s DEF14A filed with the SEC (as defined herein) on April 29, 2024. 

     

     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 3 of 4

     

     

    EXPLANATORY NOTE

     

    This Amendment No. 3 (the “Amendment”) to Schedule 13D is being filed with the Securities and Exchange Commission (the “SEC”) on behalf of OPKO Health, Inc., a Delaware corporation (“OPKO”) and relates to the Class A common stock, par value $0.0001 per share (“GeneDx Common Stock”), of GeneDx Holdings Corp., a Delaware corporation (“GeneDx” or the “Issuer”) and amends and supplements the initial statement on Schedule 13D filed by OPKO with the SEC on May 9, 2022, as amended by Amendment No. 1 to Schedule 13D filed with the SEC on February 3, 2023, as amended by Amendment No. 2 filed with the SEC on April 20, 2023  (the “Schedule 13D”).  Capitalized terms used but not defined in this Amendment No. 3 shall have the same meanings ascribed to them in the Schedule 13D.

     

    ITEM 4.

    Purpose of Transaction.

     

    Item 4 is amended by adding the following paragraph to the end of the item:

     

    In a series of transactions between July 1, 2024 and July 3, 2024, OPKO sold a total of 89,082 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price of approximately $2,457,285.

     

    ITEM 5.

    Interest in Securities of the Issuer.

     

    Item 5 is deleted in its entirety and replaced with the following text:

     

    (a)          The Company’s beneficial ownership of GeneDx Common Stock is as set forth in the table below:

     

    Name and Title of Beneficial Owner

     

    Number of Outstanding Shares Beneficially Owned

     

    Percentage of Outstanding Common Shares (1)

    OPKO Health, Inc.

     

    3,469,521

     

    13.27%

    ______________

    (1)  Based on 26,15,866 shares of GeneDx Common Stock (as defined herein) of the Issuer (as defined herein) outstanding on April 24, 2024, as set forth in the Issuer’s DEF14A filed with the SEC (as defined herein) on April 29, 2024.

     

     

    (b)          Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5.

     

    (c)          In the last 60 days prior to the filing of this Amendment No. 3, OPKO sold a total of 89,082 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price of approximately $$2,457,285. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days.

    Date

     

    Shares of Common Stock

     

    Aggregate Purchase Price

     

    Price Per

    Share

    7/1/24   50,000  

    $

    1,331,669  

    $

    26.6340
    7/2/24   25,000  

    $

    728,095  

    $

    29.1238
    7/3/24   14,082   $ 397,491   $ 28.2269

     

    (d)          Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them.

     

    (e)          Not applicable.

     

     

     

     

     

    CUSIP No. 81663L200

    Schedule 13D

    PAGE 4 of 4

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

              OPKO Health, Inc.
             

    Dated:

    July 5, 2024      

    By:

      /s/ Steven D. Rubin
             

    Name:

      Steven D. Rubin
             

    Title:

     

    Executive Vice President - Administration

                   

     

     
    Get the next $WGS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    5/15/2025$88.00Buy
    Guggenheim
    5/9/2025$80.00Hold → Buy
    Jefferies
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/16/25 4:00:06 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      5/12/25 7:46:55 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      6/5/24 8:45:06 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GeneDx Announces Publication of SeqFirst Study Demonstrating Need for First Tier Rapid Genomic Testing for Non-Critical Care Pediatric Inpatients in The Journal of Pediatrics

      --Data demonstrates that rapid genomic testing dropped the average time to a precise genetic diagnosis from almost ten months to 13 days --Despite broad utilization in the study, rapid genomic sequencing in non-critical care inpatients yielded a diagnostic rate over 42%, comparable to critical care settings --Study supports broader adoption of rapid genomic testing in the non-critical care inpatient setting to improve pediatric patient outcomes and lower healthcare costs GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced new data from the SeqFirst study team conducted in partnership with the clinical genetics team at Seattle

      6/25/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces American Academy of Pediatrics Recommends Exome and Genome Sequencing as First-Tier Tests for Children with Global Developmental Delay or Intellectual Disability

      -- A milestone in pediatric medicine, general pediatricians are now expected to play a more active role in initiating genetic testing -- -- Earlier use of exome and genome testing delivers better clinical outcomes and reduces costs across the U.S. healthcare system1 -- -- GeneDx will lead education and adoption efforts to end the diagnostic odyssey -- GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, announces the American Academy of Pediatrics (AAP) issued updated guidance to now recommend exome and genome sequencing as first-tier tests for children with global developmental delay (GDD) or intellectual disability (ID) in most circumstances

      6/23/25 3:17:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases

      Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditar

      6/23/25 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on GeneDx with a new price target

      Guggenheim initiated coverage of GeneDx with a rating of Buy and set a new price target of $88.00

      5/15/25 8:11:58 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx upgraded by Jefferies with a new price target

      Jefferies upgraded GeneDx from Hold to Buy and set a new price target of $80.00

      5/9/25 8:38:50 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Wells Fargo initiated coverage on GeneDx with a new price target

      Wells Fargo initiated coverage of GeneDx with a rating of Equal Weight and set a new price target of $34.00

      8/28/24 7:58:09 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    SEC Filings

    See more
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      7/1/25 7:53:14 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Holdings Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - GeneDx Holdings Corp. (0001818331) (Filer)

      6/18/25 4:11:49 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • SEC Form 144 filed by GeneDx Holdings Corp.

      144 - GeneDx Holdings Corp. (0001818331) (Subject)

      6/9/25 7:22:40 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Stueland Katherine sold $878,181 worth of shares (9,657 units at $90.94), decreasing direct ownership by 66% to 4,940 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      7/3/25 2:32:36 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • CHIEF FINANCIAL OFFICER Feeley Kevin sold $122,471 worth of shares (1,344 units at $91.12), decreasing direct ownership by 15% to 7,425 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      7/3/25 2:31:38 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Director Casdin Eli converted options into 12,924 shares, increasing direct ownership by 170% to 20,518 units (SEC Form 4)

      4 - GeneDx Holdings Corp. (0001818331) (Issuer)

      6/23/25 5:50:55 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology

    $WGS
    Leadership Updates

    Live Leadership Updates

    See more
    • GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

      Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program

      1/2/25 4:01:00 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

      Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

      11/18/24 8:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WGS
    Financials

    Live finance-specific insights

    See more
    • GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

      Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

      4/30/25 6:30:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

      GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2025 before the market opens on Wednesday, April 30, 2025. Management will host a conference call that day to discuss first quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone de

      4/8/25 8:05:00 AM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025

      Grew fourth quarter 2024 revenues1 to $95.3 million Expanded fourth quarter 2024 adjusted gross margins1,2 to 70% Generated fourth quarter 2024 adjusted net income2 of $16.8 million FY 2025 revenue guidance of $350M to $360M, exome/genome volume and revenue growth of at least 30% GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the fourth quarter and full year of 2024. "The fourth quarter capped an outstanding year for GeneDx, as we work to end the diagnostic odyssey with earlier intervention using our industry-leading exome and gen

      2/18/25 6:00:00 AM ET
      $BIIB
      $PRAX
      $STOK
      $WGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Retail: Computer Software & Peripheral Equipment

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/20/24 9:36:13 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/19/24 8:00:24 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology
    • Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

      SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

      11/8/24 5:23:34 PM ET
      $WGS
      Retail: Computer Software & Peripheral Equipment
      Technology